Novavax CEO Stan Erck to Participate in Longwood Healthcare Leaders Meeting
On April 5, 2021, Novavax (Nasdaq: NVAX) announced that CEO Stanley C. Erck will participate in a panel discussion at the Longwood Healthcare Leaders 2021 Webconference on April 6, 2021. The discussion, titled Progress Towards Sustainable Vaccines for COVID-19, will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. The panel is scheduled for 7:30 – 8:00 a.m. EDT and will be moderated by Harvard's Michael Mina. Novavax is at the forefront of developing innovative vaccines to combat serious infectious diseases, including COVID-19.
- None.
- None.
GAITHERSBURG, Md., April 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion during the virtual Longwood Healthcare Leaders 2021 Webconference taking place April 5-6. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Panel details are as follows:
Date: | Tuesday, April 6, 2021 |
Time: | 7:30 – 8:00 a.m. Eastern Daylight Time (EDT) |
Location: | |
Title: | Progress Towards Sustainable Vaccines for COVID-19 |
Novavax | Stanley C. Erck, CEO Moderator: Michael Mina, Asst. Professor, Epidemiology, Harvard School of Public Health |
For more information or to register for the meeting, visit: www.longwoodhealthcareleaders.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Novavax Forward Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Jennifer Porcelli | 617-974-8659
jporcelli@soleburytrout.com
Media
Laura Keenan | 410-419-5755
media@novavax.com
View original content:http://www.prnewswire.com/news-releases/novavax-ceo-stan-erck-to-participate-in-longwood-healthcare-leaders-meeting-301262027.html
SOURCE Novavax, Inc.
FAQ
What is the date of the Longwood Healthcare Leaders Webconference where NVAX CEO will speak?
What time will Stanley C. Erck speak at the Longwood Healthcare Leaders Webconference?
What is the main topic of discussion for Novavax at the Longwood Healthcare Leaders Webconference?
Who is moderating the panel discussion featuring NVAX CEO Stanley C. Erck?
Where can I register for the Longwood Healthcare Leaders Webconference?
